Calvin Sandra sold $335K of TVTX
Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) sold 5,375 shares of Travere Therapeutics, Inc. (TVTX) at an average of $62.33 ($62.14–$63.66, $0.34M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is routine and does not provide new strategic insight into the company's operations or financial outlook.
Market read
Limited relevance; typical insider sale with modest dollar amount.
What to watch
Potential future insider purchases under the same 10b5-1 plan could offset the sale.
Background
Travere Therapeutics (TVTX) is a biopharma company focused on rare kidney diseases. Insider transactions are regularly disclosed via Form 4.
Ticker impact
SVP and CAO Calvin Sandra sold 5,375 shares for $335K via a 10b5-1 plan, reducing his stake to 42,353 shares.
Minimal impact; price likely unchanged.
The sale size is modest relative to market cap and follows a pre‑arranged plan, so traders should not expect a significant reaction.
Market effects
None; biotech sector unaffected by a single insider sale.
No regional effect.
No global relevance.
Counterpoint
If the insider had a larger stake, the sale could signal concerns, but here the amount is trivial.
Key entities
- companyTravere Therapeutics, Inc.
Issuer of the Form 4 filing.
- personCalvin Sandra
SVP, Chief Accounting Officer and reporting insider.
